Literature DB >> 15578877

Severe acute respiratory syndrome: overview with an emphasis on the Toronto experience.

Tony Mazzulli1, Kevin Kain, Jagdish Butany.   

Abstract

OBJECTIVE: To provide an overview of the severe acute respiratory syndrome (SARS) outbreak in Toronto, Ontario, which experienced the largest outbreak outside Asia, and to review what has been learned during the past year. DATA SOURCES: MEDLINE search of all studies related to SARS, including review of the Centers for Disease Control and Prevention, World Health Organization (WHO), and Health Canada Web sites. DATA SYNTHESIS: During the SARS outbreak in Toronto, 438 people had been diagnosed as having suspected or probable SARS and 44 people died. Elderly people and those with comorbid illnesses were at greatest risk of complications or death. Transmission was via direct contact with respiratory secretions. The use of gloves, gowns, N95 masks, and eye protection was effective in preventing transmission. No transmission occurred before symptom onset or after recovery. Serologic tests suggest that antibodies may not appear until 28 days after illness onset. Molecular tests give their greatest yield during the second week of illness. The value of ribavirin treatment remains questionable. The combination of interferon plus corticosteroids appears to be better than corticosteroids alone. Postmortem examination revealed pulmonary edema and evidence of diffuse alveolar damage. Very few morphological changes were noted in other organs despite the presence of viral RNA as detected by polymerase chain reaction.
CONCLUSION: On July 5, 2003, the WHO declared that the SARS outbreak was over. Since then, new cases of SARS have been reported in Asia. With global travel, the disease can rapidly spread throughout the world. Therefore, we must remain vigilant to prevent another pandemic.

Entities:  

Mesh:

Year:  2004        PMID: 15578877     DOI: 10.5858/2004-128-1346-SARSOW

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

1.  Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.

Authors:  George D Liatsos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 2.  Development of antiviral therapy for severe acute respiratory syndrome.

Authors:  Jindrich Cinatl; Martin Michaelis; Gerold Hoever; Wolfgang Preiser; Hans Wilhelm Doerr
Journal:  Antiviral Res       Date:  2005-04-26       Impact factor: 5.970

Review 3.  SARS, avian flu, bioterror: infection control awareness for the optometrist.

Authors:  Santos Shan-Yu Tseng
Journal:  Clin Exp Optom       Date:  2007-01       Impact factor: 2.742

4.  Similarities of immune reactions between hepatitis C and severe acute respiratory syndrome-associated coronavirus infections.

Authors:  Wu-Shiung Huang; Rong-Fu Chen; Kuender D Yang
Journal:  J Gastroenterol Hepatol       Date:  2005-10       Impact factor: 4.029

5.  Was WHO SARS-related travel advisory for Toronto ethical?

Authors:  Leo J Paquin
Journal:  Can J Public Health       Date:  2007 May-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.